Nevirapine
A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Requires a 14-day 'lead-in' period with a half-dose to reduce the risk of severe rash.
Dosage by Body Weight
Dosed by body surface area (BSA) or weight bands. Requires strict adherence to prevent viral resistance.
- Body Weight
- 6-13 kg
- Dose
- 50 mg
- Frequency
- Twice daily (after lead-in)
- Tracking Notes
- Monitor liver enzymes and watch for rashes.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| 6-13 kg | 50 mg | Twice daily (after lead-in) | Monitor liver enzymes and watch for rashes. |
Formulation
Purpose
Part of antiretroviral therapy (ART) for HIV-1 and prevention of transmission.
Generic Name
NevirapineBranded Drug Names
Nevirapine is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
Safety Advice
Alcohol
CAUTIONNevirapine: Alcohol may worsen dizziness, nausea, dehydration, or liver strain during antiviral treatment. Avoid or limit alcohol.
Pregnancy
SAFE IF PRESCRIBEDNevirapine: Use during pregnancy only when prescribed; treatment may be important for maternal infection control or prevention of transmission.
Breast Feeding
SAFE IF PRESCRIBEDNevirapine: Breastfeeding advice depends on the infection and treatment regimen. Use only with healthcare provider guidance.
Driving
CAUTIONNevirapine: May cause dizziness, fatigue, sleep disturbance, or headache. Avoid driving if alertness is affected.
Liver
CAUTIONNevirapine: Some antivirals can affect liver function or require monitoring in hepatitis, HIV, or severe illness.
Kidney
CAUTIONNevirapine: Several antivirals are cleared by the kidneys and may need dose adjustment or hydration. Consult your healthcare provider.